Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

PRIMARY OBJECTIVES:

I. To determine the maximum tolerated dose (recommended phase 2 dose, RP2D) of lenalidomide,
when given in combination with fixed-dose durvalumab. (Phase 1) II. To assess the safety and
tolerability of the lenalidomide/durvalumab regimen, and accompanying dose modification plan,
by evaluation of toxicities including: type, frequency, severity, attribution, time course
and duration. (Phase 1) III. To evaluate the anti-tumor activity durvalumab (MEDI4736) as
single agent therapy and as part of combination therapy (+lenalidomide); activity assessed by
overall response rate (ORR). (Phase 2)

SECONDARY OBJECTIVES:

I. To estimate and assess response duration and survival probabilities (overall and
event-free). (Phase 2) II. To summarize and assess toxicities by type, frequency, severity,
attribution, time course and duration. (Phase 2) III. To assess clinically meaningful
reduction in pruritus (CMRP) in patients with CTCL (critical quality of life measure). (Phase
2)

TERTIARY OBJECTIVES:

I. To identify the malignant CD4+ T cells within the skin microenvironment. II. To
characterize the spatial and functional relationship of malignant T cells with other immune
cells, their expression of key immune checkpoints and correlate with response.

III. To identify aberrantly expressed micro(mi) ribonucleic acid (RNA)s involved in cutaneous
T-cell lymphoma (CTCL) and messenger (m)RNAs that may predict response and/or
treatment-related toxicity.

IV. To evaluate whether or not the identified miRNAs are involved in regulating key immune
checkpoints.

OUTLINE: This is a phase I, dose-escalation study of lenalidomide followed by a phase II
study. Patients are randomized to 1 of 2 arms,

ARM I: Patients receive durvalumab intravenously (IV) over 1 hour on day 1. Treatment repeats
every 28 days (+/- 3) for up to 13 courses in the absence of disease progression or
unacceptable toxicity.

ARM II: Patients receive durvalumab IV over 1 hour on day 1 and lenalidomide orally (PO) once
daily (QD) on days 1-21. Treatment repeats every 28 (+/- 3) days for up to 13 courses in the
absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for up to 12 months.

Inclusion Criteria:

- Documented informed consent of the participant and/or legally authorized
representative

- Registered into Revlimid REMS program

- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

- Fully recovered from acute toxicities (except alopecia) of all prior therapies to
Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1

- Relapsed/refractory disease

- Failed >= 2 prior systemic therapies *NOTE: For systemic ALCL prior systemic therapy
must also include progression on brentuximab vedotin

CUTANEOUS T-CELL LYMPHOMA (CTCL) ONLY

- Histologically confirmed mycosis fungoides (MF) or Sezary syndrome (SS); Phase 1: >=
stage IIB OR >= stage IB-IIA folliculotropic/transformed MF; Phase 2: >= stage IB

- Stage of disease according to TNMB classification

- Pathology report must be diagnostic or be consistent with MF/SS criteria

- SS is defined as meeting T4 plus B2 criteria; where the biopsy of erythrodermic
skin may only reveal suggestive but not diagnostic histopathological features,
the diagnosis may be based on either node biopsy or fulfillment of B2 criteria

- For MF where the histological diagnosis by light microscopic examination is not
confirmed, diagnostic criteria that has been recommended by the International
Society of Cutaneous Lymphomas (ISCL) should be used

- Measurable disease per modified severity weighted assessment tool (mSWAT) and/or
Sezary count

- Baseline skin biopsy taken within 6 months available for central review submission

PERIPHERAL T-CELL LYMPHOMA (PTCL) ONLY

- Histologically confirmed PTCL as defined by World Health Organization (WHO) 2008
criteria

- Measurable and/or evaluable disease per Lugano Classification

- Absolute neutrophil count (ANC) >= 1000/mm^3

* Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is
secondary to disease involvement

- Platelets >= 100,000/mm^3

* Platelet transfusions are not permitted within 14 days of platelet assessment unless
cytopenia is secondary to disease involvement

- Total serum bilirubin =< 2.2 mg/dL

- Aspartate aminotransferase (AST) =< 2 x upper limit of normal (ULN)

- Alanine aminotransferase (ALT) =< 2 x ULN

- Creatinine clearance of >= 60 mL/min per the Cockcroft-Gault formula

- If not receiving anticoagulants: international normalized ratio (INR) AND prothrombin
(PT) =< 1.5 x ULN

* If on anticoagulant therapy: PT must be within therapeutic range of intended used of
anticoagulants

- Female of childbearing potential: negative urine or serum pregnancy test

* If the urine test is positive or cannot be confirmed as negative, a serum pregnancy
test will be required

- Female of child bearing potential: willing to use 2 methods of birth control or be
surgically sterile, or abstain from heterosexual activity for the course of the study
through 90 days after the last dose of study medication

* Childbearing potential defined as not being surgically sterilized or have not been
free from menses for > 1 year

- Male: use an adequate method of contraception starting with the first dose of study
therapy through 90 days after the last dose of study therapy

Exclusion Criteria:

- Immunotherapy with immune checkpoint inhibitors, cell-based therapies, or cancer
vaccines

- Lenalidomide, thalidomide or other immunomodulatory drugs (IMiDs)

- Monoclonal antibody within 5 half-lives of the antibody prior to initiating protocol
therapy

- Any systemic therapy, including monoclonal antibody within 28 days or 5 half-lives
(whichever is shorter) of initiating protocol therapy

- Any skin-directed therapy within 14 days prior to initiating protocol therapy

- Any radiation therapy within 21 days prior to initiating protocol therapy

- Immunosuppressive medication within 14 days prior to the first dose of study
treatment; the following are exceptions to this criterion:

- Intranasal, inhaled, topical or local steroid injections (e.g., intra-articular
injection) and are on stable dose for at least 28 days

- Systemic corticosteroids at physiologic doses of < 10 mg/day of prednisone or
equivalent

- Live, attenuated vaccine within 30 days prior to the first dose of protocol therapy

- History of pneumonitis (non-infectious) that required steroids or current pneumonitis

- Disease free of prior malignancies for >= 5 years with the exception of:

- Currently treated squamous cell and basal cell carcinoma of the skin

- Carcinoma in situ of the cervix, or

- Surgically removed melanoma in situ of the skin (stage 0) with histological
confirmed free margins of excision or

- Prostate cancer (T1a or T1b using the TNM [tumor, nodes, metastasis] clinical
staging system) that has/have been surgically cured, or

- Any other malignancy that has/have been curatively treated with surgery and/or
localized radiation

- Allergic reaction/ hypersensitivity to thalidomide or to the excipients contained in
the formulation of durvalumab

- Female only: pregnant or lactating

- Prior stem cell transplantation

- Acute infection requiring systemic treatment

- Known history of human immunodeficiency virus (HIV) infection

- Active hepatitis B or C infection

- Conditions requiring chronic steroid or immunosuppressive treatment that likely need
additional steroid or immunosuppressive treatments in addition to the protocol therapy

- Current peripheral neuropathy >= grade 2

- Renal failure requiring hemodialysis or peritoneal dialysis

- Unstable cardiac disease as defined by one of the following:

- Cardiac events such as myocardial infarction (MI) within the past 6 months

- NYHA (New York Heart Association) heart failure class III-IV

- Uncontrolled atrial fibrillation or hypertension

- Major surgery (as defined by the investigator) within the 28 days prior to the first
dose of study treatment

- Active or prior documented autoimmune or inflammatory disorders requiring therapy
within the past 3 years prior to the start of treatment; the following are exceptions
to this criterion:

- Vitiligo or alopecia;

- Hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone
replacement; or

- Psoriasis not requiring systemic treatment

- History of primary immunodeficiency

- Incidence of gastrointestinal disease that may significantly alter the absorption of
lenalidomide

- Any other condition that would, in the investigator's judgement, contraindicate the
patient's participation in the clinical study due to safety concerns or compliance
with clinical study procedures, e.g., infection/inflammation, intestinal obstruction,
unable to swallow medication, social/psychological issues, etc

- In the opinion of the investigator, may not be able to comply with all study
procedures (including compliance issues related to feasibility/logistics)